Synairgen plc (LON:SNG – Get Free Report)’s share price fell 18.7% on Thursday . The company traded as low as GBX 4.51 ($0.06) and last traded at GBX 4.51 ($0.06). 128,570 shares were traded during mid-day trading, a decline of 62% from the average session volume of 341,639 shares. The stock had previously closed at GBX 5.55 ($0.07).
Synairgen Price Performance
The company has a current ratio of 6.77, a quick ratio of 6.35 and a debt-to-equity ratio of 0.09. The firm’s 50-day moving average price is GBX 6.23 and its 200-day moving average price is GBX 5.92. The stock has a market capitalization of £8.46 million, a PE ratio of -84.00 and a beta of -2.23.
About Synairgen
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease.
Read More
- Five stocks we like better than Synairgen
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- What is a Death Cross in Stocks?
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
